

- species barrier in prion uptake from the intestine. *J Neurosci* 2004;**24**:11280–90.
- 27 **Collinge J**. Prion diseases of humans and animals: their causes and molecular basis. *Annu Rev Neurosci* 2001;**24**:519–50.
 - 28 **Will RG**, Zeidler M, Stewart GE, *et al*. Diagnosis of new variant Creutzfeldt-Jakob disease. *Ann Neurol* 2000;**47**:575–82.
 - 29 **Hill AF**, Butterworth RJ, Joiner S, *et al*. Investigation of variant Creutzfeldt-Jakob disease and other human prion diseases with tonsil biopsy samples. *Lancet* 1999;**353**:183–9.
 - 30 **Horby P**. Variant Creutzfeldt-Jakob disease: an unfolding epidemic of misfolded proteins. *J Paediatr Child Health* 2002;**38**:539–42.
 - 31 **McDonnell G**, Burke P. The challenge of prion decontamination. *Clin Infect Dis* 2003;**36**:1152–4.
 - 32 **Hunter M**. Inquiry into handling of CJD alert welcomed. *BMJ* 2002;**325**:1055.
 - 33 **Collinge J**. Variant Creutzfeldt-Jakob disease. *Lancet* 1999;**354**:317–23.
 - 34 **Sneath PHA**. Estimation of the size of the vCJD epidemic. *Antonie van Leeuwenhoek* 2004;**86**:93–103.
 - 35 **Kmietowicz Z**. Patients informed of increased risk of vCJD contact. *BMJ* 2004;**329**:702.
 - 36 **Spinney L**. vCJD epidemic could be first of many, experts warn [News]. *Nat Med* 2003;**9**:1096.
 - 37 **Frosh A**, Smith LC, Jackson CJ, *et al*. Analysis of 2000 consecutive UK tonsillectomy specimens for disease-related prion protein. *Lancet* 2004;**364**:1260–2.
 - 38 **Myers R**, Marans K, MacDonald M. Huntington's disease. In: Wells R, Warren S, eds. *Genetic instabilities and hereditary neurological diseases*. San Diego, CA: Academic Press, 1998:301–23.
 - 39 **Delatycki MB**, Tassicker R. Adult onset neurological disorders: predictive genetic testing. *Aust Fam Physician* 2001;**30**:948–52.
 - 40 **International Huntington Association and the World Federation of Neurology Research Group on Huntington's Chorea**. Guidelines for the molecular genetics predictive test in Huntington's disease. *J Med Genet* 1994;**31**:555–9.
 - 41 **Binedell J**, Soldan JR, Harper PS. Predictive testing for Huntington's disease: predictors of uptake in South Wales. *Clin Genet* 1998;**54**:477–88.
 - 42 **Almqvist EW**, Bloch M, Brinkman R, *et al*. A worldwide assessment of the frequency of suicide, suicide attempts, or psychiatric hospitalisation after predictive testing for Huntington disease. *Am J Hum Genet* 1999;**64**:1293–304.
 - 43 **Bird T**. Outrageous fortune: the risk of suicide in genetic testing for Huntington disease. *Am J Hum Genet* 1999;**64**:1289–92.
 - 44 **Sobel SK**, Cowan DB. Impact of genetic testing for Huntington disease on the family system. *Am J Med Genet* 2000;**90**:49–59.
 - 45 **Meiser B**, Dunn S. Psychological effects of genetic testing for Huntington's disease: an update of the literature. *West J Med* 2001;**174**:336–40.
 - 46 **Human Genetics Commission (UK)**. Inside information: balancing interests in the use of personal genetic data. 2002. <http://www.hgc.gov.uk> (accessed 1 Feb 2005).
 - 47 **Gregori L**, McCombie N, Palmer D, *et al*. Effectiveness of leucoreduction for removal of infectivity of transmissible spongiform encephalopathies from blood. *Lancet* 2004;**364**:529–31.

Notice

Ethical aspects of the new genetics: what we all need to know

This one day conference and debate is open to all and will take place at the Cheltenham Town Hall on Friday 18 November 2005.

Tickets are £10 and are available from Gloucestershire Federation of WI's, 2 Brunswick Square, GL1 1UL, tel: 01452 23 96 66; email: liz@gfhi.org.uk. For further information visit www.gfwi.org.uk

A limited number of free tickets funded by the Institute of Medical Ethics are available to health care students. Apply with staff confirmation of student status by sending a SAE to Maureen Bannatyne, Institute of Medical Ethics, St Chloe, The Avenue, Old Bussage, Glos GL6 8AT.